Century Therapeutics earnings release, May 13, 2026

Century Therapeutics, Inc. (IPSC) · Form 8-K, Item 2.02 · Filed · SEC filing

Century Therapeutics Reports First Quarter Financial Results and Business Updates

PHILADELPHIA, May 13,

2026

-- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the first quarter ended March 31, 2026, and recent business highlights.

“We are executing our pipeline with discipline to deliver an iPSC-derived islet replacement therapy to patients. The progress of CNTY

-

813 highlights what Century can achieve pairing our Allo

-

Evasion™ engineering with a scalable iPSC platform,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. “In a relatively short time since initiating this program, we have advanced CNTY

-

813 into IND

- enabling studies on a timeline we believe is highly competitive with leading efforts in the field. With an IND submission expected in the fourth quarter of 2026 and initial clinical data anticipated in the second half of 2027, our focus is clear: to deliver a differentiated, patient

- centric, potentially curative approach for people with type 1 diabetes while continuing to expand our autoimmune disease portfolio with CNTY

-

308.”

First Quarter 2026 and Recent Highlights

Pipeline

Corporate

First Quarter 2026 Financial Results

About Century Therapeutics

Century

Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases, including type 1 diabetes, and cancer. The company’s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.

Financial statements

Income Statement

Three Months Ended — (unaudited, in thousands, except share and per share amounts)

Three Months Ended – March 31, 2026Three Months Ended – March 31, 2025
Collaboration Revenue$-109,164
Operating ExpensesResearch and development17,10526,580
Operating ExpensesGeneral and administrative6,5798,408
Operating ExpensesTotal operating expenses23,68434,988
Operating ExpensesIncome (loss) from operations-23,68474,176
Operating ExpensesInterest income2,0192,422
Operating ExpensesOther income (loss)20-38
Operating ExpensesTotal other income2,0392,384
Operating ExpensesNet income (loss)-21,64576,560
Operating ExpensesUnrealized loss on investments-615-19
Operating ExpensesComprehensive income (loss)-22,26076,541
Operating ExpensesNet income (loss) per common share Basic and Diluted-0.110.89
Operating ExpensesWeighted average common shares outstanding Basic193,474,91386,021,188
Operating ExpensesWeighted average common shares outstanding Diluted193,474,91386,098,619

Balance Sheet

December 31, — (unaudited, in thousands)

March 31, – 2026December 31, – 2025
Current Assets:Cash and cash equivalents51,04861,853
Current Assets:Short-term investments83,75555,261
Current Assets:Prepaid expenses and other current assets4,2363,655
Current Assets:Total current assets139,039120,769
Current Assets:Property and equipment, net47,60650,026
Current Assets:Operating lease right-of-use assets20,97216,139
Current Assets:Long-term investments82,169
Current Assets:Intangible assets34,20034,200
Current Assets:Other long-term assets2,5672,570
Current Assets:Total assets326,553223,704
Current liabilities:Accounts payable3,1504,773
Current liabilities:Accrued expenses and other liabilities8,47711,696
Current liabilities:Contingent consideration liability, short term1,9393,757
Current liabilities:Total current liabilities13,56620,226
Current liabilities:Operating lease liability, long-term43,94240,241
Current liabilities:Deferred tax liability4,3014,301
Current liabilities:Total liabilities61,80964,768
Stockholders' equityCommon stock189
Stockholders' equityAdditional paid-in capital1,078,873950,814
Stockholders' equityAccumulated deficit-813,562-791,917
Stockholders' equityAccumulated other comprehensive income-58530
Stockholders' equityTotal stockholders' equity264,744158,936
Stockholders' equityTotal liabilities and stockholders' equity326,553223,704
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements our timing and expectations regarding our preclinical and clinical development programs, including their planned development, therapeutic potential and market opportunity, ongoing and planned regulatory submissions and interactions, the achievement of developmental milestones, corporate strategies, anticipated data readouts, and our financial resources and expected cash runway are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,”

“might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,”

“anticipate,” “could,” “intend,” “target,” “project,” “contemplate,”

“believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions.

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to meet development milestones on anticipated timelines; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials; our ability to obtain clearance of our future

IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues, trade disputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission... (truncated)ww.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For More Information:

Century Therapeutics

Douglas Carr

Senior Vice President, Finance investor.relations@centurytx.com

Corey Davis, Ph.D.

LifeSci Advisors, LLC

212-915-2577 cdavis@lifesciadvisors.com

Century Therapeutics, Inc

Condensed Balance Sheets

(unaudited, in thousands)

Century Therapeutics, Inc

Condensed consolidated statements of operations

(unaudited, in thousands, except share and per share amounts)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Century Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.